| Target ID: | Tar18 |
|---|---|
| ID: | T00852 |
| Target Name: | Serine/threonine-protein kinase cot (COT) |
| Target Type: | Protein |
| CID: | -- |
| URL: | https://db.idrblab.net/ttd/data/target/details/T00852 |
| Related Drugs: | -- |
Knowledge Graph
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
Corticotropin-Releasing Hormone Receptor Alters the Tumor Development and Growt…
PMID: 33494263
Year: 2021
Relationship Type:
Correlation Studies
Score: 5.3
The neuroendocrine circuit of the corticotropin-releasing hormone (CRH) family peptides, via their cognate receptors CRHR1 and CRHR2, copes with psyc…
MicroRNA124-IL6R Mediates the Effect of Nicotine in Inflammatory Bowel Disease …
PMID: 32153570
Year: 2020
Relationship Type:
Mechanism Investigation
Score: 5.3
Epidemiological investigations have shown that smoking ameliorates ulcerative colitis (UC) but exacerbates Crohn's disease (CD), diseases that featur…
Nicotine and autoimmunity: The lotus' flower in tobacco
PMID: 29051105
Year: 2018
Relationship Type:
Mechanism Investigation
Score: 5.3
Nicotine, the major component of cigarettes, has demonstrated conflicting impact on the immune system: some authors suggest that increases pro-inflam…
The intestinal barrier as an emerging target in the toxicological assessment of…
PMID: 27417439
Year: 2017
Relationship Type:
Correlation Studies
Score: 5.3
Mycotoxins, the secondary metabolites of fungal species, are the most frequently occurring natural food contaminants in human and animal diets. Risk …
Report: pharmacotherapy for moderate to severe inflammatory bowel disease: evol…
PMID: 27269902
Year: 2016
Relationship Type:
Therapeutic Applications
Score: 5.3
Moderate to severe disease causes substantial morbidity in inflammatory bowel disease (IBD). The approach to pharmacotherapy for patients with modera…
Review article: Ulcerative colitis, smoking and nicotine therapy
PMID: 23072629
Year: 2012
Relationship Type:
Mechanism Investigation
Score: 5.3
BACKGROUND: Smoking is the best-characterised environmental association of ulcerative colitis (UC). Smoking has been observed to exert protective eff…
Expression of corticotropin releasing factor receptor type 1 (CRF1) in the huma…
PMID: 22948128
Year: 2012
Relationship Type:
Mechanism Investigation
Score: 5.3
Brain corticotropin-releasing factor (CRF) acting on CRF receptor type 1 (CRF(1)) is a main signaling pathway in the stress response. CRF is also pro…
[Optimizing antidepressant pharmacotherapy in a case of inflammatory bowel dise…
PMID: 22689282
Year: 2012
Relationship Type:
Therapeutic Applications
Score: 5.3
OBJECTIVE: In the framework of a case report on a patient suffering from major depression and inflammatory bowel disease we address the pharmacothera…
Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4 T cells me…
PMID: 21784975
Year: 2011
Relationship Type:
Therapeutic Applications
Score: 5.3
Ulcerative colitis (UC) and Crohn's disease (CD) are two forms of chronic inflammatory bowel disease. CD4 T cells play a central role in the pathogen…
Corticotrophin-releasing factor, related peptides, and receptors in the normal …
PMID: 21541251
Year: 2011
Relationship Type:
Mechanism Investigation
Score: 5.3
Corticotrophin-releasing factor (CRF) is mainly known for its role in the stress response in the hypothalamic-pituitary-adrenal axis. However, increa…
Eosinophils express muscarinic receptors and corticotropin-releasing factor to …
PMID: 21277851
Year: 2011
Relationship Type:
Clinical Research
Score: 5.3
BACKGROUND & AIMS: Altered intestinal barrier function has been implicated in the pathophysiology of ulcerative colitis (UC) in genetic, functional, …
Gaso-transmitter hydrogen sulphide: potential new target in pharmacotherapy
PMID: 21117445
Year: 2010
Relationship Type:
Therapeutic Applications
Score: 5.3
Research in the last two decades has transformed the way hydrogen sulphide (H2S) is perceived from a noxious gas to a gaso-transmitter with a vast po…
Flavokawain B inhibits NF-κB inflammatory signaling pathway activation in infla…
PMID: 38583725
Year: 2024
Relationship Type:
Mechanism Investigation
Score: 5.2
Inflammatory bowel disease (IBD) is characterized by recurrent inflammatory reactions in the intestinal mucosa, including ulcerative colitis (UC) and…
Direct inhibition of the TXNIP-NLRP3-GSDMD pathway reduces pyroptosis in colono…
PMID: 40195510
Year: 2025
Relationship Type:
Mechanism Investigation
Score: 5.0
Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The etiology of UC is multifaceted, and the underlying pathogenesis remains incomple…
A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitori…
PMID: 32311018
Year: 2021
Relationship Type:
Mechanism Investigation
Score: 5.0
Morbidity of inflammatory gastrointestinal (GI) diseases continues to grow resulting in worsen quality of life and increased burden on public medica…
Evaluation of inflammatory bowel disease activity in children using serum trefo…
PMID: 32120375
Year: 2020
Relationship Type:
Mechanism Investigation
Score: 5.0
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a class of severe and chronic diseases of the gastr…
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Ev…
PMID: 30044358
Year: 2018
Relationship Type:
Mechanism Investigation
Score: 5.0
We recently have proved that excessive fecal DCA caused by high-fat diet may serve as an endogenous danger-associated molecular pattern to activate …
Signaling pathways induced by serine proteases to increase intestinal epithelia…
PMID: 28671992
Year: 2017
Relationship Type:
Mechanism Investigation
Score: 5.0
Changes in barrier function of the gastrointestinal tract are thought to contribute to the inflammatory bowel diseases Crohn's disease and ulcerative…
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species | |
|---|---|---|---|---|---|---|---|
| bio3344 | CHEMBL1088752 | Small molecule | LOSMAPIMOD | 383.47 | C22H26FN3O2 | NEUTRAL | Details |
| bio3345 | CHEMBL450656 | Protein | ROTIGAPTIDE | 617.66 | C28H39N7O9 | NEUTRAL | Details |
| bio3346 | CHEMBL4594271 | Small molecule | BEROTRALSTAT | 562.57 | C30H26F4N6O | BASE | Details |
| bio3347 | CHEMBL5095241 | Small molecule | TUNLAMETINIB | 491.26 | C16H12F2IN3O3S | NEUTRAL | Details |
| bio3348 | CHEMBL3188267 | Small molecule | CAPMATINIB | 412.43 | C23H17FN6O | NEUTRAL | Details |
| bio3349 | CHEMBL3987016 | Small molecule | MIVEBRESIB | 459.47 | C22H19F2N3O4S | NEUTRAL | Details |
| bio3350 | CHEMBL5314585 | Small molecule | GAMCEMETINIB | 469.95 | C22H20ClN5O3S | NEUTRAL | Details |
| bio3351 | CHEMBL5315085 | Unknown | LEISHMANIA INFANTUM EXCRETED SECRETED PROTEINS | -- | -- | -- | Details |
| bio3352 | CHEMBL2104975 | Small molecule | MITRATAPIDE | 717.3 | C36H41ClN8O4S | NEUTRAL | Details |
| bio3353 | CHEMBL297884 | Small molecule | CILUPREVIR | 774.94 | C40H50N6O8S | ACID | Details |
| Strategy ID | Therapy Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||